(NASDAQ: ENLV) Enlivex Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.47%.
Enlivex Therapeutics's earnings in 2024 is -$22,294,000.On average, 1 Wall Street analyst forecast ENLV's earnings for 2024 to be -$14,618,318, with the lowest ENLV earnings forecast at -$14,618,318, and the highest ENLV earnings forecast at -$14,618,318.
In 2025, ENLV is forecast to generate -$12,112,321 in earnings, with the lowest earnings forecast at -$12,112,321 and the highest earnings forecast at -$12,112,321.